title: Prognostic Significance of Two Dimensional AgNOR Evaluation in Local Advanced Rectal Cancer Treated with Chemoradiotherapy.
abstract: The prognostic significance of AgNOR proteins in stage II-III rectal cancers treated with chemoradiotherapy was evaluated. Silver staining was applied to the 3μm sections of parafin blocked tissues from 30 rectal cancer patients who received 5-FU based chemoradiotherapy from May 2003 to June 2006. The microscopic displays of the cells were transferred into the computer via a video camera. AgNOR area (nucleolus organizer region area) and nucleus area values were determined as a nucleolus organizer regions area/total nucleus area (NORa/ TNa). The mean NORa/TNa value was found to be 9.02±3.68. The overall survival and disease free survival in the high NORa/TNa (>9.02) patients were 52.2 months and 39.4 months respectively, as compared to 100.7 months and 98.4 months in the low NORa/TNa (<9.02) cases. (p<0.001 and p<0.001 respectively). In addition, the prognosis in the high NORa/TNa patients was worse than low NORa/TNa patients (p<0.05). In terms of overall survival and disease-free survival, a statistically significant negative correlation was found with the value of NORa/TNa in the correlations tests. Cox regression analyses demostrated that overall survival and disease-free survival were associated with lymph node status (negative or positive) and the NORa/TNa value. We suggest that two-dimensional AgNOR evaluation may be a safe and usable parameter for prognosis and an indicator of cell proliferation instead of AgNOR dots.
authors.affiliation: Department of Radiation Oncology, Kayseri Education and Research Hospital, University of Erciyes, Kayseri, Turkey E-mail : mgundog@yahoo.com.
authors.forename: Mete
authors.initials: M
authors.lastname: Gundog
authors.forename: Oguz G
authors.initials: OG
authors.lastname: Yildiz
authors.forename: Nalan
authors.initials: N
authors.lastname: Imamoglu
authors.forename: Dicle
authors.initials: D
authors.lastname: Aslan
authors.forename: Aynur
authors.initials: A
authors.lastname: Aytekin
authors.forename: Isin
authors.initials: I
authors.lastname: Soyuer
authors.forename: Serdar
authors.initials: S
authors.lastname: Soyuer
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000628:therapy / Q000648:ultrastructure; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002467:Cell Nucleus / Q000473:pathology* / Q000648:ultrastructure; D059248:Chemoradiotherapy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009697:Nucleolus Organizer Region / Q000473:pathology* / Q000648:ultrastructure; D011379:Prognosis; D016622:Silver Staining; D013274:Stomach Neoplasms / Q000473:pathology* / Q000628:therapy / Q000648:ultrastructure; D015996:Survival Rate